University of Groningen

Exploring the in vitro and ex vivo efficacy of novel arginase inhibitors for the treatment of allergic asthma

Van den Berg, M. P.M.; Kurhade, S. H.; Lunev, S.; van Faassen, H J ; Bos, I. S.; Zuidhof, A. B.; Groves, M.; Kema, I P; Domling, A. S.; Meurs, H.

Published in:
Allergy

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Van den Berg, M. P. M., Kurhade, S. H., Lunev, S., van Faassen, H. J., Bos, I. S., Zuidhof, A. B., Groves, M., Kema, I. P., Domling, A. S., Meurs, H., & Gosens, R. (2018). Exploring the in vitro and ex vivo efficacy of novel arginase inhibitors for the treatment of allergic asthma. *Allergy*, 73, 343-343.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

The In Vitro and Ex Vivo Efficacy of Novel Arginase Inhibitors for the Treatment of Allergic Asthma

M. P. van den Berg¹, S. H. Kurhade², S. Lunev², H. J. van Faassen³, I. S. Bos¹, A. B. Zuidhof¹, M. Groves², I. P. Kema³, A. Dömling², H. Meurs¹, R. Gosens¹; ¹Molecular Pharmacology, University of Groningen, Groningen, Netherlands, ²Drug Design, University of Groningen, Groningen, Netherlands, ³Laboratory Medicine, University Medical Centre Groningen, Groningen, Netherlands.

Corresponding author's email: m.p.m.van.den.berg@rug.nl

Rationale: Studies in asthma patients and animal models have shown a key role for arginase isozymes in allergic airway inflammation, obstruction, hyper responsiveness and remodeling. Therefore, arginase represents a potential target for asthma treatment. The currently available arginase inhibitors are not optimal for clinical development as they lack subtype selectivity, and show limited uptake by cells and tissues due to the hydrophilic nature of the compounds. In this study, we synthesized and pharmacologically evaluated the efficacy of a novel class of arginase inhibitors. **Methods:** A colorimetric biochemical urea inhibition assay was used to generate IC₅₀-values of the novel compounds for inhibiting recombinant human arginase 1 and 2 isotypes. Precision-cut lung slices of ovalbumin sensitized male guinea pigs were treated for 30 minutes with the novel arginase inhibitors (1, 10 and 100 μ M), or reference compounds Amino-2-Borono-6-Hexanoic Acid (ABH) or SHK145 (1 μ M). Slices were used to establish ovalbumin dose response curves to examine the effect on airway narrowing. Furthermore, to examine the effect of arginase inhibition on allergen induced histamine release, the ABH treated slices were stimulated with different doses of ovalbumin for 5 minutes. Slices were homogenized and histamine levels of both homogenized tissue and supernatant were determined by HPLC-MS/MS. **Results:** IC₅₀ determination for ABH, SHK145, SHK081-2, SHK081-5 and SHK186-8 showed IC₅₀-values of 1.5, 15, 19, 25 and 0.19 μ M for recombinant human arginase 1 and 2.5, 10, 20, 85 and 0.24 for arginase 2 respectively. Treatment of lung slices with 1 μ M ABH resulted in a significant decrease in ovalbumin induced airway narrowing, decreased E_{max} and increased EC₅₀, compared to control. The efficacy of 1, 10 and 100 μ M SHK081-2, SHK081-5 and SHK186-8 was comparable to that of ABH. Interestingly, slices pretreated with 1 μ M SHK145 showed a significant increase in E_{max}, but not EC₅₀ or ovalbumin induced airway narrowing, compared to slices pretreated with 1 μ M ABH ($p < 0.05$). Experiments to determine histamine levels after ovalbumin challenge show a reduction in histamine release after treatment with 1 μ M ABH compared to control. **Conclusions:** We have shown that the novel compounds are able to inhibit the arginase enzymes in vitro and ex vivo in a similar fashion as ABH. Furthermore, we show that arginase regulates allergic airway narrowing by influencing histamine release by mast cells. These findings bring us a step closer to the development of novel arginase inhibitors for the treatment of allergic asthma.

This abstract is funded by: STW

Am J Respir Crit Care Med 2018;197:A5806

Internet address: www.atsjournals.org

Online Abstracts Issue